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We previously reported that the suppression of SIRT2, an NAD+-dependent 
protein deacetylases, induces p53 accumulation via degradation of p300 and the 
subsequent MDM2 degradation, eventually leading to apoptosis in HeLa cells. The 
present study identified a novel pathway of p53 accumulation by SIRT2 suppression in 
HCT116(p53+/+) cells in which SIRT2 suppression led to escape from mitotic cell 
death caused by spindle assembly checkpoint activation induced by microtubule 
inhibitors such as nocodazole but not apoptosis or G1 or G2 arrest. We found that 
SIRT2 interacts with P/CAF, a histone acetyltransferase, which also acts as a ubiquitin 
ligase against MDM2. SIRT2 suppression led to an increase of P/CAF acetylation and 
its stabilization followed by a decrease in MDM2 and activation of the p53-p21 pathway. 
Depression of mitotic cell death in HCT116(p53+/+) cells with SIRT2 suppression was 
released by suppression of P/CAF or p21. Thus, the P/CAF-MDM2-p53-p21 axis 
enables the escape from mitotic cell death and confers resistance to nocodazole in 
HCT116(p53+/+) cells with SIRT2 suppression. As SIRT2 has attracted attention as a 
potential target for cancer therapeutics for p53 regulation, the present study provides a 
molecular basis for the efficacy of SIRT2 for future cancer therapy based on p53 
regulation. These findings also suggest an undesirable function of the SIRT2 
suppression associated with activation of the p53-p21 pathway in the suppression of 
mitotic cell death caused by spindle assembly checkpoint activation. 
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Mammalians express seven sirtuins (SIRT1–7), a family of NAD+-dependent 
protein deacetylases that differ widely in their specificity towards substrates, 
localization, and biological functions including cancer, and aging [1] .  
Recently, SIRT2 has attracted attention as a potential target for cancer 
therapeutics, as it has been reported that SIRT2 functions as a tumor suppressor by 
regulating mitosis and genome integrity [2]. Furthermore, SIRT2-deficient mice exhibit 
tumorigenesis in multiple organs [2].  
As a different mechanism of how SIRT2 suppresses tumorigenesis, our group 
showed that SIRT2 modulates the spindle assembly mitotic checkpoint (SAC) in the 
colorectal cancer cell line HCT116 expressing wild-type p53 [hereafter referred as to 
HCT116(p53+/+)], a mitotic checkpoint proficient near-diploid cell line [3]. It is known 
that suppression of BubR1 and Mad2, key molecules in the mitotic checkpoint, leads to 
resistance to microtubule inhibitors (MTIs) such as nocodazole by abolishing SAC 
function [4]. As is the case for the suppression of BubR1 and Mad2, SIRT2 suppression 
confers resistance to MTIs in HCT116(p53+/+) cells [3]. However, SIRT2 suppression 
prolongs SAC activation, suggesting that SIRT2 regulates mitotic cell death caused by 
SAC activation via a different mechanism from BubR1 and Mad2. Prolonged SAC 
activation in cells with SIRT2 suppression is thought to reflect escape from mitotic cell 
death, which is also observed for the case of Myc suppression leading to the inhibition 
of mitotic cell death [5]. 
In contrast to the function of SIRT2 as a tumor suppressor, SIRT2 inactivation 
was shown to have potential in cancer therapy. We previously reported that SIRT2 




was caused by p53 accumulation, which is mediated by degradation of p300, which acts 
as a dual regulator of p53 via acetylase and polyubiquitin ligase (E4) activities [6].  
In our previous study of SIRT2 function in mitotic cell death [3], we observed 
that SIRT2 suppression does not result in apparent apoptotic cell death or cell cycle 
arrest in HCT116(p53+/+) cells in the absence of MTIs, unlike in HeLa cells. We also 
observed that SIRT2 suppression confers resistance to nocodazole in HCT116(p53-/-) 
cells in which the p53 gene was disrupted by homologous recombination with 
HCT116(p53+/+) cells, although the extent of resistance is much lower than in 
HCT116(p53+/+) cells [3]. Therefore, we initially hypothesized that p53 accumulation 
does not occur in HCT116(p53+/+) cells with SIRT2 suppression or is not involved in 
mitotic cell death. Based on this hypothesis, we evaluated the mechanism of how p53 
accumulation by SIRT2 suppression is inhibited in HCT116(p53+/+) cells to improve 
the efficacy of inhibitors of sirtuins on tumor toxicity.  
Unexpectedly, we observed that the p53-p21 pathway is induced in 
HCT116(p53+/+) cells with SIRT2 suppression in the present study. Here, we describe a 
novel pathway for SIRT2 in p53 regulation, in which SIRT2 controls p53 levels by 
regulating the stability of P/CAF, a histone acetyltransferase, which also acts as a 
ubiquitin ligase toward MDM2, a ubiquitin ligase that targets p53 [7]. Furthermore, we 
found that P/CAF accumulation followed by activation of the p53-p21 pathway 
mediates at least partially the escape from mitotic cell death in HCT116(p53+/+) cells 
with SIRT2 suppression. The present study revealed a novel pathway for p53 regulation 
by SIRT2 and also indicates a negative aspect of SIRT2 suppression with activation of 





2. Materials and methods 
2.1 Cell culture and siRNA transfection 
Cell culture anf siRNA transfection were performed as previously reported [8]. 
siRNAs corresponding to SIRT2 and p21 mRNAs were obtained from Qiagen 
(HP-validated siRNAs) (SIRT2, SI02655471; p21, SI00604905). siRNA corresponding 
to P/CAF mRNA was obtained from Thermo Fisher Scientific (s16895). . siRNA 
corresponding to p300 mRNA was designed as previously reported [9]. Negative 
control siRNA was obtained from Qiagen (1027281).  
Nocodazole (Millipore) was resuspended in dimethyl sulfoxide (Sigma) and 
used at a final concentration of 200 nM. Cycloheximide (Wako) was resuspended in 
ethanol and used at a final concentration of 75 µg/ml. AGK2 (Cayman Chemical) was 
resuspended in dimethyl sulfoxide and used at a final concentration of 10 µM. 
 
2.2 Plasmids 
pcDNA3-Myc-SIRT2(wt) and pcDNA3-Myc-SIRT2(∆NDAC) constructs were 
described in our previous report [8]. pCI flag PCAF was obtained from Addgene.  
Transfection to 293T cells were performed using PEI Max (Polysciences). 
 
2.3 Immunoblotting 
Antibodies are listed in Supplementary Material 1. Signals were visualized with 






Cellular extracts were prepared from cell pellet by adding 8 volumes of Triton 
X-100 lysis buffer [20 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.2 % Triton X-100, 2 
mM EGTA, 1.5 mM MgCl2, and 10 % glycerol] containing a protease inhibitor mixture 
(Roche), phosphatase inhibitor mixture (Roche), and 5 mM nicotinamide (Wako). 
Immunoprecipitations were carried out with 500 µL of cell extract in the 
presence of 2.5 µg of antibody and 10 µL Protein G Sepharose (GE Healthcare) for 12 h 
at 4°C. Anti-P/CAF antibody (Cell signaling), anti-SIRT2 antibody (Abcam)  and 
anti-FLAG M2 antibody (Sigma) were used. To examine the interaction between SIRT2 
and P/CAF in vivo, 500 µL of cell extract was precleared in the presence of 2.5 µg of 
normal rabbit IgG (Cell signaling) and 10 µL Protein G Sepharose for 8 h at 4°C, and 
then used for immunoprecipitation. Immune complexes were washed 4 times with 
Triton X-100 lysis buffer, and then eluted with 50 µL of SDS-PAGE sample buffer. 
 
2.4 Real-time RT-PCR 
Total RNA was prepared using NucleoSpin RNA (Macherey-Nagel) and 500 ng 
of RNA was used to synthesize cDNA using a ReverTra Ace kit (Toyobo). Real-time 
PCR was carried out in triplicate on a StepOne Plus Real Time PCR System (Applied 
Biosystems) using Thunder-bird SYBR qPCR Mix (Toyobo) and the following primers: 
P/CAF primers: forward: GCCACAGTTCTGCGACAGTCT, reverse: 
CCGAGCGAAGCAATGTTCTC; GAPDH primers: forward: 
TGTCCGTCGTGGATCTGAC, reverse: CCTGCTTCACCACCTTCTTG. 
 
2.5 Flow cytometry analysis 





3.1 SIRT2 suppression leads to activation of the p53-p21 pathway through 
upregulation of P/CAF 
In our previous study, we observed that siRNA-mediated SIRT2 knockdown 
does not result in apparent apoptotic cell death or cell cycle arrest in HCT116(p53+/+) 
cells, unlike in HeLa [3,6]. Thus, we originally hypothesized that p53 is not upregulated 
in HCT116(p53+/+) cells with SIRT2 suppression and aimed to determine the difference 
in p53 regulation by SIRT2 between HCT116(p53+/+) and HeLa cells. However, 
unexpectedly, immunoblotting analysis showed that SIRT2 suppression in 
HCT116(p53+/+) cells led to increased expression of p53 (Fig. 1A). Additionally, the 
expression of p21, a transcription target of p53, was induced in HCT116(p53+/+) cells 
with SIRT2 suppression (Fig. 1A).  
As the molecular basis for p53 accumulation in cells with SIRT2 suppression, 
we reported that in HeLa cells, SIRT2 suppression causes p53 accumulation by 
decreasing p300 [6], which acts as a dual regulator of p53 [10]. Thus, we examined the 
level of p300 in HCT116(p53+/+) and HCT116(p53-/-) cells with SIRT2 suppression. 
As shown in Figure 1B, a minor decrease in p300 was observed in HCT116(p53+/+) 
and HCT116(p53-/-) with SIRT2 suppression, whereas a significant decrease in p300 
was observed in HeLa cells as we previously reported [6]. Importantly, siRNA-mediated 
p300 suppression in HCT116(p53+/+) cells did not cause p53 accumulation or p21 
accumulation unlike the case of HeLa cells in our previous study [6] (Fig. 1B). These 
results indicates that a minor decrease in p300 does not mediate p53 accumulation in 
HCT116(p53+/+) cells with SIRT2 suppression.   




also acts as a ubiquitin ligase toward MDM2, a ubiquitin ligase that targets p53 [7]. 
Furthermore, SIRT1 was reported to interact with P/CAF through the conserved 
catalytic core domain of sirtuin proteins and deacetylate P/CAF [11]. Interestingly, 
immunoblotting analysis showed that SIRT2 suppression led to increased P/CAF levels 
and decreased MDM2 levels in HCT116(p53+/+) cells (Fig. 1A). 
P/CAF expression has been reported to be induced by p53 in breast tumor cells 
[12]. To examine whether the increase in P/CAF was a cause or consequence of p53 
accumulation in HCT116(p53+/+) cells with SIRT2 suppression, we performed 
siRNA-mediated P/CAF knockdown in HCT116(p53+/+) cells with SIRT2 suppression. 
As shown in Figure 1A, we observed that MDM2, p53, and p21 levels in 
HCT116(p53+/+) cells with SIRT2 suppression were restored to levels similar to those 
in control cells by knockdown of P/CAF. We obtained the same results in 
HCT116(p53-/-) cells (Fig. 1A ). These results demonstrate that the increase in P/CAF 
in HCT116(p53+/+) cells with SIRT2 suppression caused a decrease in MDM2 
followed by p53 accumulation and that P/CAF accumulation was p53-independent.  
We examined whether the P/CAF-MDM2-p53-p21 axis is also active in cells 
with SIRT2 suppression during SAC activation, to investigate later whether this axis is 
responsible for conferring resistance to mitotic cell death. The optimal length of 
treatment with nocodazole was determined to be 16 h to achieve SAC activation, as 
monitored by cyclin B1/Cdk1 activity and the MPM-2-positive population, which 
reached a peak at 16 h of treatment in both cells with SIRT2 knockdown and control 
cells in our previous study [3]. Immunoblotting analysis revealed similar results for all 
proteins (Fig. 1A), suggesting that the P/CAF-MDM2-p53-p21 axis is active in cells 





3.2 SIRT2 interacts with P/CAF and controls P/CAF protein stability  
To determine the mechanism of how SIRT2 suppression decreased P/CAF, we 
examined whether SIRT2 interacts with P/CAF and controls P/CAF stability, based on a 
previous study showing that SIRT1 interacts with P/CAF through the conserved 
catalytic core domain of sirtuins that deacetylate P/CAF [11]. 293T cells were 
cotransfected with FLAG-tagged P/CAF and SIRT2 expression vectors. When the 
whole cell extracts were immunoprecipitated with an anti-FLAG antibody, SIRT2 was 
detected in the FLAG immunoprecipitate (Fig. 2A), suggesting that SIRT2 interacts 
with P/CAF. SIRT2 (∆NDAC), a mutant version of SIRT2 lacking deacetylase activity, 
also interacts with FLAG-P/CAF (Fig. 2A).  
We also examined whether SIRT2 deacetylates P/CAF, which is autoacetylated 
and acetylated by p300[13]. We examined the levels of acetyl-lysine in the FLAG 
immunoprecipitates by immunoblotting analysis of anti-acetyl-lysine antibody. As 
shown in Figure 2A, SIRT2(wt) expression reduced acetylation of P/CAF; however, 
SIRT2 (∆NDAC) expression also reduced acetylation of P/CAF to a similar extent. This 
suggests that the complex formation of SIRT2 and P/CAF but not deacetylase activity of 
SIRT2 reduced acetylation of P/CAF, unlike SIRT1 [11].  
We next examined whether SIRT2 interacts with P/CAF in a physiological 
context. When whole cell extracts of HCT116(p53+/+) cells were precipitated with 
anti-SIRT2 antibody, endogenous P/CAF was detected in the SIRT2 immunoprecipitate 
(Fig. 2B). To further confirm that the band in the immunoblot of P/CAF was derived 
from endogenous P/CAF, the whole cell lysate from HCT116(p53+/+) cells with 




antibody (Fig. 2B). We observed that endogenous SIRT2 was immunoprecipitated with 
high efficiency by the anti-SIRT2 antibody (Fig. 2B). This demonstrates that SIRT2 
interacts with P/CAF in a physiological context. We attempted reciprocal detection of 
SIRT2 in the P/CAF immunoprecipitate; however, we did not detect SIRT2 in the 
P/CAF immunoprecipitate (Fig. 2B). This may be because of the low efficiency of 
immunoprecipitation by the anti-P/CAF antibody (Fig. 2B). 
We analyzed the P/CAF acetylation level in a physiological context. When the 
whole cell lysates were immunoprecipitated with anti-P/CAF antibody, P/CAF 
acetylation was not detected in immunoblotting analysis (data not shown). However, the 
reciprocal approach was successful (Fig. 2C). As shown in Figure 2C, SIRT2 
suppression increased the level of P/CAF acetylation. Furthermore, we observed that the 
level of P/CAF acetylation was not increased by treatment with AGK2, a potent and 
selective SIRT2 inhibitor (Fig. 2D). This result is consistent with the observation that 
the interaction of SIRT2 but not its deacetylase activity reduced acetylation of P/CAF 
(Fig. 2A). Additionally, the levels of P/CAF, MDM2, p53, and p21 were not changed by 
treatment with AGK2 (Fig. 2D). These results not only support that the increased level 
of P/CAF by SIRT2 suppression leads to a decrease in MDM2 followed by increases in 
p53 and p21, but also indicates that the increased level of P/CAF acetylation leads to 
P/CAF accumulation in HCT116(p53+/+) cells with SIRT2 suppression. 
We examined whether SIRT2 reduces the protein stability of P/CAF as a 
mechanism to explain how SIRT2 suppression causes P/CAF accumulation, although 
the effect of the interaction between SIRT1 on P/CAF on the protein stability of P/CAF 
is unknown [11]. We analyzed the protein stability of endogenous P/CAF in 




Figure 3A, P/CAF stability was increased in HCT116(p53+/+) cells with SIRT2 
suppression compared to in control cells. Real-time RT-PCR analysis did not reveal 
significant changes in P/CAF mRNA levels between these cells (Fig. 3B). These results 
suggest that SIRT2 reduces the protein stability of P/CAF. The complex formation of 
SIRT2 and P/CAF followed by reduced acetylation of P/CAF may be a mechanism to 
reduce the protein stability of P/CAF.    
 
3.3 P/CAF-MDM2-p53-p21 axis confers resistance to mitotic cell death caused by 
SAC activation 
Our previous results suggest that both p53-dependent and p53-independent 
pathways conferring resistance to nocodazole exist in cells with SIRT2 suppression [3]. 
The results obtained in the present study prompted us to examine whether the 
p53-dependent pathway is mediated by the P/CAF-MDMs-p53-p21 axis. 
To test this possibility, we performed clonogenic cell survival assays after 
nocodazole treatment (0–60 h) for HCT116(p53+/+) and HCT116(p53-/-) cells with 
siRNA-mediated knockdown of P/CAF or p21 alone or in combination with SIRT2, or 
SIRT2 alone. We performed also cell cycle analyses after nocodazole treatment by 
assessing the DNA content in the cells.  
Clonogenic cell survival assays showed that both in HCT116(p53+/+) and 
HCT116(p53-/-) cells, resistance to nocodazole was observed in cells with knockdown 
of SIRT2 alone, as compared to in control cells, particularly at 24 h of treatment (Fig. 
4A). The patterns of cell cycle progression and accumulation from 2C to 4C were 
similar among all samples for up to 16 h of treatment with nocodazole (Fig. 4B). In our 




activity and the MPM-2-positive population reached a peak at 16 h of treatment in both 
HCT116(p53+/+) cells with SIRT2 suppression and in control cells; additionally, cells 
with SIRT2 suppression showed prolonged mitotic arrest and SAC activation [3]. 
Although p21 is increased in HCT116(p53+/+) cells with SIRT2 suppression. (Fig. 1A), 
apparent G1 arrest or G2 arrest was not observed (Fig. 4A). Importantly, suppression of 
P/CAF or p21 significantly reduced the resistance to nocodazole in HCT116(p53+/+) 
cells with SIRT2 suppression, but not in HCT116(p53-/-) cells with SIRT2 suppression 
(Fig. 4A). This suggests that escape from mitotic cell death in HCT116(p53+/+) cells 
with SIRT2 suppression is mediated by P/CAF accumulation followed by activation of 
the p53-p21 pathway. 
Cells with >4C content began to appear after 36 h and increased in number up to 
48 h among control cells; however, the population with >4C DNA content was 
significantly lower in HCT116(p53+/+) cells with SIRT2 suppression than in control 
cells (Fig. 4A). These results are the same as our previously reported results [3]. 
Chromosome number analysis study showed that nearly all cell colonies in clonogenic 
cell survival assays after nocodazole treatment were derived from mitotic arrested cells 
that escaped from mitotic cell death and underwent a subsequent shift to the diploid G1 
phase after removing nocodazole [3]. Thus, the population with >4C DNA in the 
presence of nocodazole is thought to reflect the population that underwent mitotic 
slippage followed by polyploidization at an early stage of mitotic arrest. Its delayed 
appearance is thought to reflect the increase in the population that escaped from mitotic 
cell death and finally underwent to mitotic slippage at the late stage in the presence of 
nocodazole, which is also observed for the case of Myc suppression leading to the 




Cell cycle analysis showed that suppression of P/CAF or p21 increased cell 
population with the >4C content of HCT116(p53+/+) cells with SIRT2 suppression (Fig. 
4B). The degree of the increase was much lower in HCT116(p53-/-) cells than 
HCT116(p53+/+) cells (Fig. 4B). Thus, the results obtained by clonogenic cell survival 
assays and cell cycle analyses suggest that the P/CAF-MDM2-p53-p21 axis is 








In the present study, we identified a novel pathway of p53 accumulation by 
SIRT2 suppression in HCT116(p53+/+) cells, in which SIRT2 suppression did not cause 
a significant down-regulation of p300, unlike HeLa cells (Fig. 1B). We found that 
SIRT2 interacts with P/CAF, a histone acetyltransferase that also acts as a ubiquitin 
ligase toward MDM2 (Fig. 2), and that SIRT2 suppression leads to P/CAF stabilization 
followed by degradation of MDM2, a ubiquitin ligase towards p53 (Fig. 1A and 3). This 
pathway may account for the previous observation by Matsushita et al. that the 
transcriptional activity of p53 is up-regulated in SIRT2-deficient chicken DT40 cells 
[14].  
SIRT1 deacetylates p53, resulting in inhibition of p53 activity, and SIRT1 is a 
therapeutic target for cancer harboring wild-type p53. SIRT1 inactivation has been the 
most extensively studied anti-cancer drug among the SIRT family [15]. Our study 
showed that SIRT2 inactivation, as well as SIRT1 inactivation, may be a novel 
molecular target for cancer therapy to control p53 regulation.  
However, the use of SIRT2 suppression for p53 activation in cancer therapy can 
be complicated, as our present study also suggests that SIRT2 suppression associated 
with activation of the p53-p21 pathway confers resistance to anti-cancer drug such as 
MTIs, at least in HCT116(p53+/+) cells with SIRT2 suppression. Consistent with this 
observation, paclitaxel and mitotic kinase inhibitors including Plk1 or Aurora kinase 
inhibitors cause an increase in p21 during M phase in surviving tumor cells, and 
enhanced p21 promotes the survival of treated cells [16].  
Our results suggest that the p53-p21 pathway functions to protect cells from 




effective inhibitor of cyclin B1/Cdk1 in vivo, some studies indicated a direct role of p21 
in regulating cyclin B1/Cdk1 activity in mitosis [17]. We previously reported that cyclin 
B1/Cdk1 was not inhibited and cell cycle progression from 2C to 4C was not altered in 
HCT116(p53+/+) cells with SIRT2 suppression, despite enhanced p21 expression (Fig. 
1A) [3]. This suggests that the induction of p21 protects cells with SIRT2 suppression 
from mitotic cell death by cyclinB1/Cdk1-independent mechanisms. 
The divergent function of p21 including tumor suppressive and oncogenic 
functions depend on the amount, localization, modification, and cellular context [18]. 
Among the diverse functions of p21, several candidates have been reported to be 
involved in cell death by SAC activation. For example, the repression of 
Myc-dependent transcription by p21 is a candidate mechanism, as Myc promotes 
mitotic cell death by SAC activation by upregulating a cluster of redundant 
pro-apoptotic BH3-only proteins and suppressing pro-survival Bcl-xL [5]. Repression 
of caspase-2 by p21 is also a candidate mechanism, as caspase-2 has been reported to 
trigger mitotic catastrophe [19]. Revealing these mechanisms is important for targeting 
SIRT2 as a promising molecule to regulate p53 in cancer therapy.  
The present study demonstrated that SIRT2 functions as a regulator of P/CAF 
stabilization in addition to p53. P/CAF plays a role in diverse biological processes, such 
as chromatin remodeling, transcriptional regulation, DNA repair, cell cycle progression, 
differentiation, and cell death [20]. The present study suggests that SIRT2 also functions 
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Figure Legends  
Fig. 1 SIRT2 suppression leads to increased P/CAF levels, decreased MDM2 levels, 
and activation of the p53-p21 pathway. 
(A) HCT116(p53+/+) and HCT116(p53-/-) cells were transfected with siRNAs to the 
indicated genes or negative control siRNA, followed by culture for 16 h in the presence 
or absence of nocodazole. Changes in p53, p21, P/CAF, MDM2, and SIRT2 were 
determined by immunoblotting. (B) HCT116(p53+/+) ,HCT116(p53-/-), and HeLa cells 
were transfected with siRNAs to the indicated genes, followed by culture for 16 h in the 
presence or absence of nocodazole. Changes in p300, p53, p21, and SIRT2 were 
determined by immunoblotting. Note that HCT116 cells express a truncated form of 
p300.  
 
Fig. 2 Physical interaction between SIRT2 and P/CAF, and reduced level of P/CAF 
acetylation by the interaction. 
(A) 293T cells were transfected with a combination of expression plasmids as indicated. 
Whole cell lysates were immunoprecipitated by anti-FLAG antibody and then subjected 
to immunoblotting analysis using anti-SIRT2 antibody. The levels of FLAG-P/CAF 
acetylation in immunoprecipitates were examined by immunoblotting analysis using 
anti-acetylated lysine antibody. (B) Interaction of SIRT2 and P/CAF in vivo. 
HCT116(p53+/+) cells were transfected with siRNA to P/CAF and the negative control 
siRNA. Whole cell lysates were immunoprecipitated by anti-SIRT2 antibody and 
anti-P/CAF antibody, and then subjected to immunoblotting analysis using anti-P/CAF 
antibody. Detection of SIRT2 in immunoprecipitates obtained with anti-SIRT2 antibody 




anti-SIRT2 antibody, SIRT2 was not detected in the immunoprecipitate obtained with 
anti-P/CAF antibody, possibly because of the low efficiency of the precipitation. (C) 
Increased level of P/CAF acetylation in HCT116(p53+/+) cells with SIRT2 suppression. 
Whole cell lysates were immunoprecipitated by anti-acetylated lysine and then 
subjected to immunoblotting analysis using anti-P/CAF antibody and anti-acetylated 
lysine antibody. (D) Treatment with the SIRT2 inhibitor AGK2 does not increase P/CAF 
acetylation to activate the P/CAF-MDM2-p53-p21 axis. HCT116(p53+/+) cells were 
treated with AGk2 (10 µM), a selective SIRT2 inhibitor with an IC50 of 3.5 μM for 36 h 
[21].  
 
Fig. 3 SIRT2 suppression stabilizes P/CAF 
(A) Time course of P/CAF protein stability in HCT116(p53+/+) cells with SIRT2 
suppression and control cells after treatment with 75 µg/mL cycloheximide. β-Actin 
was used as an internal control. Quantification of the immunoblotting was performed 
with Image J software (NIH). A similar result was obtained in an independent 
experiment (supplementary figure 1). (B) Real-time RT-PCR analysis of P/CAF mRNA 
in HCT116(p53+/+) cells with SIRT2 suppression and control cells. The expression of 
GAPDH was used as an internal control.  
 
Fig. 4 Resistance to nocodazole and prolonged mitotic arrest in the presence of 
nocodazole in HCT116(p53+/+) cells with SIRT2 downregulation is abolished by 
knockdown of P/CAF or p21.  
(A) Clonogenic cell survival assays for HCT116(p53+/+) and HCT116(p53-/-) cells 




incubated in the presence of nocodazole for the indicated times, incubated in drug-free 
medium for 8–10 days. Assays were performed in triplicate and error bars denote 
standard deviation. (B) Cell cycle analyses for cells transfected with siRNAs to the 
indicated genes. DNA content and the ratio of >4C population, which reflect mitotic 


























p53 rabbit Santa Cruz Biotechnology sc-6243 1:1000, Immunoreaction Enhancer Solution (Toyobo) 
MDM2 mouse Calbiochem OP46 1:350, 3 % skim milk/TBS-T(0.05 %) 
P/CAF  rabbit Cell Signaling Technology #3378 1:2000, Immunoreaction Enhancer Solution 
p21 rabbit Cell Signaling Technology #2947 1:2000, 1 % bovine serum albumin/TBS-T(0.05 %) 
p300 rabbit Cell Signaling Technology #70088 1:2000, Immunoreaction Enhancer Solution  
SIRT2 rabbit Sigma HPA011165 1:1000, Immunoreaction Enhancer Solution  
SIRT2 rabbit Abcam  EPR20411-105 1:1000, Immunoreaction Enhancer Solution  
acetylated lysine rabbit Cell Signaling Technology #9441 1:1000, 1 % bovine serum albumin/TBS-T(0.05 %) 
 β-actin mouse 
 
Sigma A5441 1:8000, 1 % bovine serum albumin/TBS-T(0.05 %) 
Rabbit  IgG HRP-linked Donkey GE Healthcare NA934              1:4000 
 Mouse IgG HRP-linked 
 
  
Sheep GE Healthcare NA931          1:4000 
 
 
     
  









   
 
                                                                                                          
 
SIRT2 suppression stabilizes P/CAF. Time course of P/CAF protein stability in HCT116(p53+/+) cells with SIRT2 suppression 
and control cells after treatment with 75 µg/mL cycloheximide. β-Actin was used as an internal control. Quantification of the 
immunoblotting was performed with Image J software (NIH). This experiment was performed in an independent manner from 
the experiment shown in figure 3A. 
